Ovid Therapeutics Inc. (OVID)

Name: Ovid Therapeutics Inc. (OVID) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001636651 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Ovid Therapeutics Inc. reported revenue of $7.25M. Over the twelve months to 2026-06-30, revenue was $1.58M.

Key ratios (year ended 2025-12-31)

-585.2%

Operating margin

-240.1%

Net margin

-13.3%

Return on year-end equity

n/m

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$1.58M	$7.25M	$566.0K	$392.0K	$1.50M	$208.38M	$12.62M	n/a	n/a	n/a	n/a
R&D Expense	$33.60M	$25.58M	$36.77M	$28.59M	$24.62M	$46.94M	$63.42M	$42.16M	$33.79M	$49.97M	$9.59M
Operating Income	-$58.36M	-$42.44M	-$61.88M	-$59.28M	-$55.55M	$124.21M	-$81.43M	-$61.41M	-$52.93M	-$65.01M	-$22.54M
Depreciation & Amortization	$84.0K	$273.0K	$613.0K	$568.0K	$512.5K	$237.1K	$306.8K	$255.0K	$141.7K	$80.3K	$56.5K
EBITDA	-$58.27M	-$42.17M	-$61.27M	-$58.71M	-$55.04M	$124.45M	-$81.12M	-$61.15M	-$52.79M	-$64.93M	-$22.48M
Net Income	-$34.49M	-$17.41M	-$26.43M	-$52.34M	-$54.17M	$122.83M	-$81.04M	-$60.46M	-$51.98M	-$64.81M	-$22.41M
EPS (Diluted)	n/a	n/a	n/a	-$0.74	-$0.77	$1.76	-$1.39	n/a	n/a	n/a	n/a
Total Assets	$231.97M	$150.93M	$92.17M	$144.03M	$155.27M	$194.54M	$75.93M	$80.84M	$47.65M	$89.46M	$53.03M
Total Liabilities	$22.08M	$20.27M	$23.94M	$56.23M	$22.99M	$14.80M	$32.29M	$10.82M	$8.84M	n/a	n/a
Shareholders' Equity	$209.89M	$130.66M	$68.23M	$87.80M	$132.27M	$179.75M	$43.63M	$70.02M	$38.81M	$83.44M	$49.29M
Cash & Equivalents	$11.33M	$13.15M	$26.30M	$27.04M	$44.87M	$187.80M	$72.03M	$41.90M	$36.49M	$87.13M	$51.94M
Operating Cash Flow	-$54.77M	-$38.33M	-$55.96M	-$45.78M	-$55.23M	$118.61M	-$51.58M	-$51.09M	-$45.56M	-$31.47M	-$17.80M
Capital Expenditures	n/a	$0	$71.0K	$40.0K	$1.22M	$184.0K	$127.2K	$57.2K	$33.9K	$38.9K	$30.4K
Free Cash Flow	n/a	-$38.33M	-$56.03M	-$45.82M	-$56.45M	$118.43M	-$51.71M	-$51.15M	-$45.59M	-$31.51M	-$17.83M
Shares Outstanding	184.76M	130.18M	71.01M	70.69M	70.47M	70.36M	65.74M	54.71M	24.65M	24.61M	9.84M
Weighted Average Diluted Shares	n/a	n/a	n/a	70.58M	70.42M	68.07M	58.45M	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	n/a	n/a	-$0.74	-$0.77	$1.78	-$1.39	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView